MREO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mereo BioPharma Group PLC (MREO) is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, bearish technical indicators, and recent downgrades by analysts suggest that the stock does not present a compelling opportunity for long-term investment. Additionally, there are no significant positive catalysts or trading signals to justify an immediate buy.
The technical indicators are bearish. The stock's moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 46.975, and the MACD histogram is positive but contracting, showing no strong momentum. The stock is trading near its pivot level of 0.327, with resistance at 0.347 and support at 0.308.
No significant positive catalysts identified. The stock has a slight pre-market gain of 4.08%, but this is not supported by broader trends or news.
Recent downgrades by JPMorgan to Neutral from Overweight due to missed primary endpoints in key trials and uncertainty in the regulatory process. Financial performance is weak, with negative EPS and no revenue growth.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$7.35M, and a significant drop in EPS (-83.33% YoY). Gross margin remains high at 73.4%, but this is not enough to offset the lack of profitability.
JPMorgan recently downgraded the stock to Neutral from Overweight, citing missed trial endpoints and regulatory uncertainty. This reflects a negative sentiment from analysts.
